GDTC
CytoMed Therapeutics Limited · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website 2.cytomed.sg
- Employees(FY) -
- ISIN SGXZ17669631
Performance
+2.37%
1W
+8.0%
1M
+2.61%
3M
-46.93%
6M
-55.92%
YTD
-51.02%
1Y
Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Technical Analysis of GDTC 2024-05-03
Overview:
In the last 5 trading days, GDTC stock has shown mixed signals across various technical indicators. The trend indicators suggest a slightly bearish sentiment, with the stock price hovering around the moving averages. Momentum indicators indicate a weakening trend, while volatility remains relatively stable. Volume indicators show a con...
Recent News & Updates
- 2024-03-19 20:30
- 2024-03-17 18:00
- 2024-03-03 16:00
- 2024-01-28 18:00
- 2023-12-04 18:30
- 2023-11-16 20:21
- 2023-11-13 18:47
- 2023-10-24 01:00
- 2023-09-24 19:00
- 2023-08-28 21:00
- 2023-08-16 19:30
- 2023-08-15 01:00
- 2023-07-31 19:00
- 2023-07-26 21:00
- 2023-07-13 22:52
- 2023-07-05 19:00
- 2023-06-27 21:00
- 2023-05-10 21:00
CytoMed Therapeutics to Ring Nasdaq Closing Bell(Yahoo Finance)
- 2023-05-08 22:07
- 2023-04-13 08:00
Page 1 of 1
previousnext